tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Amneal Pharmaceuticals Seeks $1.8 Billion in New Loans

Story Highlights
Amneal Pharmaceuticals Seeks $1.8 Billion in New Loans

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Amneal Pharmaceuticals ( (AMRX) ) has shared an update.

On July 21, 2025, Amneal Pharmaceuticals announced that its subsidiary, Amneal Pharmaceuticals LLC, is seeking to borrow $1.8 billion in new seven-year term B loans and has launched a $750 million private offering of senior secured notes due 2032. The proceeds from these financial activities are intended to refinance existing term B loans, repay a portion of outstanding amounts under its ABL facility, and cover related fees and expenses. These transactions are subject to market conditions, and there is no assurance of their completion. The notes will be offered to qualified institutional buyers and non-U.S. persons, and will not be registered under the Securities Act of 1933.

The most recent analyst rating on (AMRX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.

Spark’s Take on AMRX Stock

According to Spark, TipRanks’ AI Analyst, AMRX is a Neutral.

Amneal Pharmaceuticals’ overall score is driven by solid revenue growth and a positive earnings call outlook, despite high leverage and profitability challenges. The lack of valuation appeal and neutral technical indicators moderate the score.

To see Spark’s full report on AMRX stock, click here.

More about Amneal Pharmaceuticals

Amneal Pharmaceuticals, headquartered in Bridgewater, NJ, is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of over 280 pharmaceuticals, primarily in the United States. The company is expanding in complex product categories and therapeutic areas, including injectables and biosimilars, and has a growing portfolio of branded pharmaceuticals focused on central nervous system and endocrine disorders. Through its AvKARE segment, Amneal also distributes pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets.

Average Trading Volume: 1,765,281

Technical Sentiment Signal: Buy

Current Market Cap: $2.5B

For an in-depth examination of AMRX stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1